Literature DB >> 9085173

Characterization of complement C3, C4, and factor B molecules in human bile.

K Sumiyoshi1, A Andoh, Y Fujiyama, H Sakumoto, T Bamba.   

Abstract

We performed molecular analysis of complement components (C3, C4, and factor B) in human bile by sodium dodecyl sulfate-polyarylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Complement C3 was detected as a molecule composed of a 115-kDa alpha-chain linked to a 70-kDa beta-chain by disulfide bonds, and C3 levels ranged from 45 to 650 micrograms/ml (n = 15). C4 was detected as a triple chain (98-kDa alpha-chain, 73-kDa beta-chain, and 33-kDa gamma-chain) molecule linked by disulfide bonds, and C4 levels ranged from 2.5 to 60 micrograms/ml. Factor B, a component of the alternative pathway, was also detected, as an intact form. Factor B levels ranged from 0.3 to 8.0 micrograms/ml. The sizes and subunit structures of complement components in human bile were compatible with those reported in human serum. The results of a hemolytic assay indicated that complement molecules in human bile were functionally active. These molecules may participate in local immune and inflammatory responses in the biliary tract.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085173     DOI: 10.1007/bf02936373

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  20 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Complement in local biliary tract defense: dissociation between bile complement and acute phase reactants in cholecystitis.

Authors:  P B Wilton; A P Dalmasso; M O Allen
Journal:  J Surg Res       Date:  1987-04       Impact factor: 2.192

4.  Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.

Authors:  W Zhang; P J Lachmann
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

5.  Immunohistochemical localization of secretory component in the liver of guinea pigs and dogs versus rats, rabbits, and mice.

Authors:  D L Delacroix; G Furtado-Barreira; J Rahier; C Dive; J P Vaerman
Journal:  Scand J Immunol       Date:  1984-05       Impact factor: 3.487

6.  Activation of the alternative pathway of complement by twelve different rabbit-mouse chimeric transfectoma IgA isotypes.

Authors:  R D Schneiderman; T F Lint; K L Knight
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

7.  IgA plasma cells in biliary mucosa: a likely source of locally synthesized IgA in human hepatic bile.

Authors:  H Nagura; Y Tsutsumi; H Hasegawa; K Watanabe; P K Nakane; W R Brown
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

8.  Human C'3: evidence for the liver as the primary site of synthesis.

Authors:  C A Alper; A M Johnson; A G Birtch; F D Moore
Journal:  Science       Date:  1969-01-17       Impact factor: 47.728

9.  Immunoglobulins in rabbit hepatic bile: selective secretion of IgA and IgM and active plasma-to-bile transfer of polymeric IgA.

Authors:  D L Delacroix; A M Denef; G A Acosta; P C Montgomery; J P Vaerman
Journal:  Scand J Immunol       Date:  1982-10       Impact factor: 3.487

10.  IGA in human bile and liver.

Authors:  H Nagura; P D Smith; P K Nakane; W R Brown
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

View more
  1 in total

1.  Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice.

Authors:  Tomoki Aomatsu; Hirotsugu Imaeda; Kenichiro Takahashi; Takehide Fujimoto; Eiji Kasumi; Hiromitsu Ban; Shigeki Bamba; Atsushi Yoden; Hiroshi Tamai; Yoshihide Fujiyama; Akira Andoh
Journal:  J Clin Biochem Nutr       Date:  2012-11-20       Impact factor: 3.114

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.